Residency · Residency · General Surgery

Hemostasis, Coagulation, and Blood Product Transfusion

Overview

A thorough understanding of hemostasis and coagulation is essential for surgical practice. The surgeon must recognize and manage coagulopathies, understand anticoagulant reversal, guide blood product transfusion, and apply viscoelastic testing in acute hemorrhage. Mastery of these principles directly affects patient survival in the operating room and the intensive care unit.

Normal Hemostasis

Primary Hemostasis (Platelet Plug)

When vascular injury exposes subendothelial collagen and von Willebrand factor (vWF), primary hemostasis begins. Platelet adhesion occurs as platelets bind collagen via the glycoprotein Ib-IX-V receptor complex, a process mediated by vWF. Activation follows, with platelets undergoing a shape change and degranulating to release ADP, thromboxane A2, and serotonin. Finally, platelet aggregation completes the primary plug as platelets crosslink through glycoprotein IIb/IIIa receptors bound by fibrinogen. Primary hemostasis is assessed clinically by platelet count, the historical bleeding time, and the more modern PFA-100 assay.

Secondary Hemostasis (Coagulation Cascade)

The traditional cascade model divides coagulation into three pathways. The intrinsic pathway involves Factors XII, XI, IX, and VIII and is assessed by the aPTT. The extrinsic pathway involves tissue factor and Factor VII and is assessed by the PT/INR. The common pathway -- where these converge -- involves Factor X, Factor V, prothrombin (Factor II), and fibrinogen (Factor I) and is assessed by both the PT/INR and aPTT.

The cell-based model of coagulation provides a more physiologically accurate understanding. During initiation, a tissue factor-bearing cell complexes with Factor VIIa to generate a small amount of thrombin. In the amplification phase, this thrombin activates platelets and Factors V, VIII, and XI on the platelet surface. During propagation, a large-scale thrombin burst occurs on the activated platelet surface, converting fibrinogen to fibrin. Factor XIII then crosslinks the fibrin strands to stabilize the clot.

Fibrinolysis

The fibrinolytic system balances clot formation by breaking down fibrin. Plasminogen is converted to plasmin by tissue plasminogen activator (tPA), and plasmin degrades the fibrin clot into fibrin degradation products (FDPs) and D-dimers. This process is regulated by plasminogen activator inhibitor-1 (PAI-1) and alpha-2 antiplasmin. Tranexamic acid (TXA), a lysine analog that inhibits plasminogen activation, has become a critical tool in managing hemorrhage.

Natural Anticoagulants

The body maintains several natural anticoagulant mechanisms. Antithrombin III inhibits thrombin and Factor Xa, and heparin enhances its activity approximately 1000-fold. Protein C and Protein S inactivate Factors Va and VIIIa and are vitamin K-dependent. Tissue factor pathway inhibitor (TFPI) inhibits the TF-VIIa complex that initiates coagulation.

Coagulation Testing

Standard Tests

The PT/INR assesses the extrinsic and common pathways (Factors VII, X, V, II, and fibrinogen) and is the standard test for monitoring warfarin therapy. The aPTT assesses the intrinsic and common pathways (Factors XII, XI, IX, VIII, X, V, II, and fibrinogen) and monitors unfractionated heparin. The platelet count provides a quantitative assessment only and does not reflect platelet function. The fibrinogen level is normally 200 to 400 mg/dL, with a critical threshold below 100 mg/dL in the setting of active bleeding. The D-dimer is a sensitive but nonspecific marker for fibrin degradation, elevated in DIC, pulmonary embolism, DVT, postoperative states, trauma, and sepsis. The thrombin time detects heparin effect, fibrinogen abnormalities, and the presence of FDPs.

Viscoelastic Testing (TEG/ROTEM)

Thromboelastography (TEG) and rotational thromboelastometry (ROTEM) provide point-of-care assessment of whole blood clotting, offering real-time analysis of clot formation, strength, and fibrinolysis. TEG parameters include the R-time (reflecting clotting factor activity), K-time and alpha angle (reflecting fibrinogen function), maximum amplitude or MA (reflecting platelet function and fibrinogen), and LY30 (reflecting fibrinolysis at 30 minutes). The corresponding ROTEM parameters are clotting time (CT), clot formation time (CFT), maximum clot firmness (MCF), and maximum lysis (ML). These tests guide goal-directed blood product transfusion in trauma, cardiac surgery, and liver transplantation, providing rapid results in 15 to 30 minutes, detecting hyperfibrinolysis, and reducing unnecessary transfusion.

Common Coagulopathies in Surgical Patients

Disseminated Intravascular Coagulation (DIC)

DIC involves widespread activation of coagulation with simultaneous consumption of clotting factors and platelets. It is triggered by sepsis, trauma, malignancy (especially acute promyelocytic leukemia), obstetric emergencies, massive transfusion, and traumatic brain injury. Laboratory findings include prolonged PT and aPTT, low fibrinogen, low platelets, elevated D-dimer, and schistocytes on peripheral smear. Treatment centers on addressing the underlying cause while providing supportive replacement with fresh frozen plasma, cryoprecipitate for fibrinogen repletion, and platelets.

Trauma-Induced Coagulopathy (TIC)

Trauma-induced coagulopathy is pathophysiologically distinct from DIC. It is driven by tissue hypoperfusion, activation of the protein C pathway, and hyperfibrinolysis, and is exacerbated by the lethal triad of hypothermia, acidosis, and coagulopathy. Treatment involves damage control resuscitation, activation of a massive transfusion protocol, and administration of tranexamic acid within 3 hours of injury, as demonstrated by the CRASH-2 trial.

Liver Disease Coagulopathy

Liver disease produces a complex coagulopathy. The liver's impaired synthetic function reduces production of virtually all clotting factors except vWF and Factor VIII. Impaired clearance of activated clotting factors, decreased thrombopoietin production leading to thrombocytopenia, and decreased levels of natural anticoagulants (Protein C, Protein S, and antithrombin) create a state of "rebalanced hemostasis." A critically important clinical point is that the INR does not reliably predict bleeding risk in cirrhosis because both procoagulant and anticoagulant factors are reduced; viscoelastic testing is preferred for guiding hemostatic management.

Heparin-Induced Thrombocytopenia (HIT)

Type II HIT is an immune-mediated condition in which anti-PF4/heparin antibodies cause platelet activation and, paradoxically, thrombosis rather than bleeding. It typically occurs 5 to 10 days after heparin exposure, with the platelet count dropping by more than 50%. The 4T score provides clinical assessment, and confirmation requires anti-PF4 antibody testing and serotonin release assay. Management requires stopping all heparin (including line flushes), initiating alternative anticoagulation with argatroban or bivalirudin, and critically, never administering platelets and never initiating warfarin until the platelet count has recovered.

Anticoagulant Reversal

Warfarin

Warfarin reversal depends on urgency. Vitamin K (phytonadione) at 10 mg IV provides reversal with an onset of 6 to 12 hours; 1 to 2.5 mg orally suffices for non-urgent situations. Fresh frozen plasma at 10 to 15 mL/kg provides immediate but temporary reversal. 4-factor prothrombin complex concentrate (Kcentra), dosed at 25 to 50 units/kg based on INR, is preferred over FFP for rapid reversal because it is faster, requires a smaller volume, does not need thaw time, and contains Factors II, VII, IX, X along with Proteins C and S. Three-factor PCC lacks adequate Factor VII and is less effective.

Unfractionated Heparin

Protamine sulfate reverses unfractionated heparin at a dose of 1 mg protamine per 100 units of heparin given in the preceding 2 to 3 hours, with a maximum single dose of 50 mg. It carries a risk of anaphylaxis, particularly in patients with fish allergy, prior protamine exposure, or history of vasectomy.

Low Molecular Weight Heparin

Protamine reverses approximately 60% of enoxaparin's anti-Xa activity, dosed at 1 mg protamine per 1 mg enoxaparin if given within 8 hours of the dose. Reversal is incomplete.

Direct Oral Anticoagulants (DOACs)

The following table summarizes reversal strategies for all major anticoagulants:

Dabigatran, a direct thrombin inhibitor, is specifically reversed by idarucizumab (Praxbind) at 5 g IV. The Factor Xa inhibitors -- rivaroxaban, apixaban, and edoxaban -- are reversed by andexanet alfa (Andexxa) or 4-factor PCC at 50 units/kg. Activated charcoal may be useful if ingestion occurred within 2 hours. Hemodialysis removes dabigatran but not the Factor Xa inhibitors.

Antiplatelet Agents

Aspirin causes irreversible COX-1 inhibition, and because the platelet lifespan is 7 to 10 days, its effect persists until new platelets are produced. Clopidogrel, prasugrel, and ticagrelor are P2Y12 receptor inhibitors. For life-threatening bleeding, platelet transfusion is the primary intervention. DDAVP (desmopressin) at 0.3 mcg/kg may improve platelet function, particularly in uremia and aspirin use.

Blood Products and Transfusion

Packed Red Blood Cells (pRBCs)

The following table summarizes key blood products, their properties, and transfusion triggers:

One unit of packed red blood cells raises hemoglobin by approximately 1 g/dL and hematocrit by 3%. They are stored at 1 to 6 degrees Celsius with a shelf life of 42 days (CPDA-1) or 35 days (AS-1). The TRICC trial established that a restrictive transfusion strategy with a hemoglobin trigger of 7 g/dL is equivalent or superior to a liberal strategy (trigger of 10 g/dL) in most patients, and this has been confirmed by the FOCUS trial. Exceptions include active coronary syndromes, where a trigger of 8 to 9 g/dL may be considered, and ongoing hemorrhage. A type and screen identifies the patient's ABO/Rh type and screens for unexpected antibodies, while a type and crossmatch confirms compatibility with a specific donor unit.

Fresh Frozen Plasma (FFP)

FFP contains all coagulation factors and is dosed at 10 to 15 mL/kg. A significant limitation is its 20 to 30 minute thaw time, which delays administration in emergent settings. Indications include coagulopathy with active bleeding, warfarin reversal when PCC is unavailable, DIC, and massive transfusion. ABO-compatible plasma is required because it contains anti-A and anti-B antibodies.

Platelets

One apheresis unit (equivalent to 6 pooled units) raises the platelet count by 30,000 to 60,000. Platelets are unique among blood products in that they are stored at room temperature (20 to 24 degrees Celsius) with agitation, giving them a shelf life of only 5 days. Transfusion triggers are below 10,000 for prophylaxis, below 50,000 for invasive procedures, and below 100,000 for neurosurgery or ocular surgery. ABO matching is preferred but not required, while Rh matching is important in women of childbearing age.

Cryoprecipitate

Cryoprecipitate is rich in fibrinogen (150 to 250 mg per unit), Factor VIII, Factor XIII, and vWF. The typical dose is 10 pooled units, with a target fibrinogen level above 150 to 200 mg/dL in active bleeding. Indications include hypofibrinogenemia, DIC, and von Willebrand disease when DDAVP is ineffective.

Massive Transfusion Protocol (MTP)

Massive transfusion is defined as 10 or more units of pRBCs in 24 hours, or 4 or more units in 1 hour with ongoing need. The PROPPR trial established that fixed-ratio transfusion at 1:1:1 (pRBC:FFP:platelets) is the preferred approach. The protocol should be activated early based on clinical assessment using tools such as the ABC score and shock index. Essential adjuncts include calcium replacement (to counteract citrate-mediated chelation of ionized calcium), tranexamic acid (1 g IV within 3 hours of injury per the CRASH-2 trial), and cryoprecipitate to maintain fibrinogen above 150 mg/dL. Complications of massive transfusion include hypothermia (mitigated by blood warmers), hypocalcemia from citrate toxicity, hyperkalemia from stored blood, metabolic alkalosis as citrate is metabolized to bicarbonate, and transfusion-related acute lung injury (TRALI).

Transfusion Reactions

Febrile non-hemolytic reactions are the most common, caused by anti-white blood cell antibodies and treated with acetaminophen; the transfusion should be stopped and a hemolytic reaction ruled out. Acute hemolytic reactions result from ABO incompatibility, almost always due to clerical error, and present with fever, flank pain, hemoglobinuria, and DIC -- the transfusion must be stopped immediately and IV fluids initiated. Delayed hemolytic reactions occur 2 to 10 days post-transfusion due to minor antigens (Kidd, Duffy, Kell), causing extravascular hemolysis with falling hemoglobin and a positive direct antiglobulin test. Allergic reactions range from simple urticaria to anaphylaxis, with the latter especially concerning in IgA-deficient patients who require IgA-deficient or washed products. TRALI is non-cardiogenic pulmonary edema occurring within 6 hours of transfusion, caused by anti-HLA or anti-HNA antibodies in donor plasma, and managed with supportive care including mechanical ventilation if needed. TACO (transfusion-associated circulatory overload) is cardiogenic pulmonary edema from volume overload, treated with diuretics.

<image>Comprehensive diagram of the cell-based model of coagulation showing three phases: Initiation (tissue factor-bearing cell with TF-VIIa complex generating small amounts of thrombin), Amplification (thrombin on platelet surface activating Factors V, VIII, XI), and Propagation (tenase and prothrombinase complexes on activated platelet surface generating thrombin burst leading to fibrin formation). Include the natural anticoagulants (antithrombin, protein C/S) and fibrinolytic system (tPA, plasmin) as regulatory pathways.</image>

<image>TEG (thromboelastography) tracing interpretation guide showing a normal TEG tracing with labeled parameters (R-time, K-time, alpha angle, MA, LY30) alongside abnormal tracings for common coagulopathies: factor deficiency (prolonged R), hypofibrinogenemia (decreased alpha angle), thrombocytopenia (decreased MA), and hyperfibrinolysis (increased LY30). Include a treatment algorithm panel showing which blood product corrects each abnormality.</image>

<image>Visual reference card for massive transfusion protocol showing the 1:1:1 ratio concept (pRBC:FFP:platelets), activation criteria (ABC score components, shock index), adjuncts (TXA timing, calcium replacement, cryoprecipitate targets), monitoring parameters, and the lethal triad of trauma (hypothermia, acidosis, coagulopathy) with targeted interventions for each component.</image>

Clinical Pearls

The TRICC trial established that a restrictive transfusion threshold of hemoglobin 7 g/dL is as safe as or safer than a liberal threshold of 10 g/dL in most critically ill patients. Massive transfusion should use a 1:1:1 ratio of pRBC to FFP to platelets as established by the PROPPR trial. Tranexamic acid must be given within 3 hours of injury in trauma per the CRASH-2 trial, as administration beyond this window may increase mortality. Calcium replacement is critical during massive transfusion because citrate in stored blood chelates ionized calcium, causing hypotension and cardiac dysfunction. HIT is a pro-thrombotic state despite thrombocytopenia, and clinicians must never give platelets and never initiate warfarin acutely. Four-factor PCC (Kcentra) is preferred over FFP for warfarin reversal due to its faster onset, smaller volume, and elimination of thaw time. Idarucizumab specifically reverses dabigatran, while andexanet alfa reverses Factor Xa inhibitors. Stored pRBCs undergo a "storage lesion" characterized by decreased 2,3-DPG (causing a left-shifted oxygen dissociation curve), increased potassium leak, and decreased deformability. In liver disease, the INR is unreliable for predicting bleeding risk because both procoagulant and anticoagulant factors are reduced, creating a state of "rebalanced hemostasis." The most common cause of an acute hemolytic transfusion reaction is a clerical error, making patient identification verification the most important safety step.

References

• Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care (TRICC). N Engl J Med. 1999;340:409-417.
• Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio (PROPPR trial). JAMA. 2015;313(5):471-482.
• CRASH-2 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients. Lancet. 2010;376:23-32.
• Levy JH, Connors JM. Heparin resistance -- clinical perspectives and management strategies. N Engl J Med. 2021;385:826-832.

Read this lecture as Markdown